<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588454</url>
  </required_header>
  <id_info>
    <org_study_id>NL64616.091.18</org_study_id>
    <nct_id>NCT04588454</nct_id>
  </id_info>
  <brief_title>18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme</brief_title>
  <acronym>PSMA-GBM</acronym>
  <official_title>18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine uptake of PET tracer 18F-PSMA-1007 in primary&#xD;
      glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioblastoma multiforme (GBM) is a highly vascularised tumour. Previous studies have shown&#xD;
      that prostate-specific membrane antigen (PSMA) is robustly expressed by the tumour vascular&#xD;
      endothelium of GBM and thus could be an interesting target for diagnosis and treatment.&#xD;
&#xD;
      Several groups have focused on the development of 18F-labeled PSMA ligands for PET imaging.&#xD;
      18F as a radionuclide has several advantages over 68Ga. Due to the longer half-life compared&#xD;
      (110 min for 18F compared to 68 min for 68Ga) allows for centralized production and&#xD;
      distribution to greater areas. Furthermore, multiple doses of 18F can be produced in one&#xD;
      synthesis, while each gallium generator provides only one or two elutions per day. Moreover,&#xD;
      due to the decreased positron energy (0.65 MeV for 18F compared to 1.90 MeV for 68Ga) imaging&#xD;
      resolution may be higher. The first generation of 18F-PSMA ligands, such as 18F-DCFBC,&#xD;
      suffered from high background due to slow blood clearance. The second generation 18F-DCFPyL&#xD;
      PSMA ligand has a fast elimination via the urinary route and showed high tumor-to-blood&#xD;
      ratios. Benesova et al developed the 177Lu-DKFZ-61, which is suitable for labelling with both&#xD;
      diagnostic 68Ga as well as therapeutic 177Lu (beta-emitting) or 225Ac (alpha-emitting), and&#xD;
      Giesel at al developed 18F-PSMA-1007, which is structurally related to DKZF-617.&#xD;
&#xD;
      Since various studies have shown feasibility of PSMA imaging in brain lesions of patients&#xD;
      with recurrent GBM, we want to extend these results in a cohort of patients with a&#xD;
      first-diagnosed suspected GBM. We want to use the PET tracer 18F-PSMA-1007. If this technique&#xD;
      can be implemented successfully, the added value of 18F-PSMA PET/CT for tumour grading and&#xD;
      differential diagnosis could be investigated further in larger patient cohorts (especially&#xD;
      with recurrent brain lesions). These studies will pave the way for further studies involving&#xD;
      177Lu-PSMA-based therapy, which is currently applied in patients with metastatic prostate&#xD;
      cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 17, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The uptake of 18F-PSMA PET/CT in suspected GBM lesions</measure>
    <time_frame>uptake of the tracer at 2 hours post injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The correlation between PSMA protein and RNA expression with 18F-PSMA PET/CT uptake</measure>
    <time_frame>uptake of the tracer at 2 hours post injection vs RNA expression determined from excised tumor tissue</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between 18F-PSMA PET/CT and T1Gd MRI</measure>
    <time_frame>Uptake of the tracer at 2 hours post injection vs pre-op MRI</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>18F-PSMA-1007 PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-PSMA-1007 PET tracer</intervention_name>
    <description>18F-PSMA-1007 PET/CT</description>
    <arm_group_label>18F-PSMA-1007 PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspected GBM on MRI scan&#xD;
&#xD;
          -  Scheduled for tumor resection at Radboudumc&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Pregnancy or the wish to become pregnant within 6 months&#xD;
&#xD;
          -  Creatinine clearance below 40ml/min&#xD;
&#xD;
          -  Liver disease defined as aspartate aminotransferase or alanine aminotransferase level&#xD;
             of more than three times the upper limit of normal range&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nuclear imaging</keyword>
  <keyword>prostate specific membrane antigen</keyword>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>positron emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

